Thyroid Cancer
399
80
110
153
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
44 trials with published results (11%)
Research Maturity
153 completed trials (38% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.0%
20 terminated out of 399 trials
88.4%
+1.9% vs benchmark
5%
21 trials in Phase 3/4
29%
44 of 153 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 153 completed trials
Clinical Trials (399)
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment
Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk Stratification and Post-Treatment Surveillance in Fresh Thyroid Cancer Patients
New MRI Biomarkers in Head and Neck Cancers
A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer
Studies on Tumors of the Thyroid
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
Ganoderma Spores Modulate the Gut-Brain Axis
DESTINY-PANTUMOUR04
An Observational Study on Postoperative Symptoms After Thyroidectomy (POS-T)
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer
Application and Evaluation of Vision-LSTM Modeling in Diagnostic Ultrasound Imaging of TI-RADS Category 4b Thyroid Nodules
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Mortality Benefit of Ultrasound for Thyroid Nodules Identified With PET Imaging: Non-Inferiority Emulated Target Trial